Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective

Vista sencilla de ítem
dc.creatorSingh, Awadhesh Kumar
dc.creatorMajumdar, Sujoy
dc.creatorSingh, Ritu
dc.creatorMisra, Anoop
dc.date.accessioned2020-07-24T15:20:02Z
dc.date.available2020-07-24T15:20:02Z
dc.date.created2020-06-25
dc.description.abstractenglishBackground and aims Interest in corticosteroid therapy in COVID-19 has been rekindled after the results from Randomized Evaluation of COVid-19 thERapY (RECOVERY) Trial. However, the World health Organization has not recommended corticosteroid in the treatment of COVID-19. We sought to conduct a systematic review on the role of corticosteroid in the management of patients of COVID-19. Methods A systematic electronic search of PubMed, Cochrane and MedRxiv database using specific keywords was made up till June 17, 2020. Full text of all the original articles with supplementary appendix that fulfilled the inclusion criteria were retrieved and a detailed analysis of results were represented. Results Of the 5 studies (4 retrospective studies and 1 quasi-prospective study) conducted for evaluating the role of corticosteroids, 3 studies have shown benefit, while 2 studies shown no benefit and there was a suggestion of significant harm in critical cases in one sub-study. RECOVERY trial is the only randomized controlled trial that has shown a significant reduction of death by 35% in ventilated patients and by 20% amongst patients on supplemental oxygen therapy with the dexamethasone, although no benefit was observed in mild cases. Conclusions While the results from retrospective studies are heterogenous and difficult to infer of a definitive protective benefit with corticosteroids, RECOVERY trial found a significantly better outcome with dexamethasone, mostly in severe cases. Nonetheless, more studies are needed to replicate the outcome shown in RECOVERY trial for a substantial conclusion.spa
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.dsx.2020.06.054spa
dc.identifier.issn1871-4021spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S187140212030223X?via%3Dihub#!spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11083
dc.publisherDiabetes & Metabolic Syndrome: Clinical Research & Reviewseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCorticosteroidsspa
dc.subjectDexamethasonespa
dc.subjectMethylprednisolonespa
dc.subjectARDSspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleRole of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspectivespa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Role-of-corticosteroid-in-the-management-of-C_2020_Diabetes---Metabolic-Synd.pdf
Tamaño:
517.24 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento Reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS